Case Report

Late Prosthetic Valve Infective Endocarditis by Enterococcus durans

Mohammed Al Shehri*, Muhammad Samsoor Zarak*, Arif R Sarwari*
Departments of Internal Medicine and Infectious Disease, West Virginia University School of Medicine, Morgantown, West Virginia, USA
*Both authors contributed to the manuscript equally.

Abstract

Enterococcus durans is an extremely rare cause of infective endocarditis. We have reported the first case where a 56-year-old female presented with late prosthetic valve infective endocarditis on a mechanical mitral valve. Medical management failed and eventually lead to the demise of the patient.

Keywords: Enterococcus durans, infective endocarditis, late prosthetic valve infective endocarditis, mechanical valve infective endocarditis

Introduction

Enterococcal endocarditis is a potential cause of devastating condition with a high morbidity and mortality rate. Enterococcus durans infective endocarditis is an extremely rare condition evident from the fact that it has only been reported seven times in the literature worldwide. Late prosthetic valve E. durans infective endocarditis of a mechanical mitral valve that failed medical management has never been reported in the literature.

Case Report

A 56-year-old Caucasian female with a history of mechanical mitral valve replacement presented to the emergency room with acute kidney injury. The patient also reported the presence of low-grade fever, fatigue, weight loss of 24 pounds, and decreased appetite for 3 months. During the period of subacute symptoms, the patient presented to the health-care system several times. The patient denied the presence of any night sweats, chills, skin rash, viral symptoms, or hemoptysis. Past medical history was positive for diabetes mellitus type 2, hypertension, and atrial fibrillation, whereas the patient had surgical history of mitral valve replacement due to severe mitral valve regurgitation, coronary artery bypass grafting, carotid endarterectomy, aortic valve repair, and placement of a surgical mesh after urinary bladder surgery. Medications at the time of admission included warfarin, amiodarone, and metoprolol. The patient was vitally stable; however, physical examination revealed a 4/6 diastolic murmur on the apical area along with significant tenderness on the left upper chest wall which radiated toward the back. The patient had no Janeway lesions and had no exposure to tame animals.

Blood workup showed pancytopenia and elevated creatinine of 5.9 mg/L, potassium of 6.1 mEq/L, C-reactive protein of 61 mg/dL, and International Normalized Ratio (INR) of 4.78. Urine analysis showed hematuria with mild proteinuria and mixed cellular cast. Light microscopic study of urine, liver function tests, serology for viral hepatitis, antinuclear antibody, antineutrophil cytoplasmic antibodies, and cryoglobulin were within the normal range. Bacterial isolates were recovered from four of four blood cultures within 14–28 h of collection using the standard automated instrumentation (BacT-Alert System, FA Plus and FN Plus bottles, BioMerieux, Durham, NC, USA). Following subculture to sheep blood agar, isolated colonies of Gram-positive cocci were evaluated in...
duplicate from each of the four cultures using MALDI-TOF mass spectrometry (Vitek MS, BioMerieux), with all giving uniformly high probability scores (99.9%) for the identity of Enterococcus durans. Antimicrobial susceptibility testing was performed on a representative isolate from each bacteremia episode using an automated phenotypic method (Vitek 2, GP75, BioMerieux) or standard disc diffusion and gradient diffusion (E-test, BioMerieux) [Figure 1]. Transesophageal echocardiogram (TEE) showed vegetation of 0.8 cm × 0.3 cm on the medial aspect of the annulus of the mechanical mitral valve [Figure 2a]. An abdominal computed tomography (CT) scan showed splenomegaly with splenic infarction. After the initial assessment, the patient was admitted to the medicine ward, and multidisciplinary teams, including nephrology, infectious disease, radiology, and cardiac surgery, were consulted.

At admission, the patient was placed on intravenous fluids as conservative management for kidney injury and empiric antibiotic therapy consisting of daptomycin, cefepime, and metronidazole was initiated, whereas warfarin was halted due to supra-therapeutic INR levels. Daptomycin was eventually switched to combination ampicillin and ciprofloxacin when blood cultures revealed Enterococcus durans sensitive to ampicillin, ciprofloxacin, daptomycin, gentamicin, and vancomycin. Gentamicin was avoided due to kidney injury. Blood cultures after 72 h of antibiotics therapy were sterile. The patient remained febrile; therefore, ampicillin was switched to daptomycin. Three months after the completion of antibiotic therapy, the patient presented to the emergency department with hemiplegia, left-sided facial palsy, and aphasia. Laboratory studies showed creatinine of 7.27 mg/dL, blood urea nitrogen of 79, and INR of 7.2. CT scan of the brain showed right frontal intraparenchymal hemorrhage with subarachnoid extension and a 3-mm leftward midline shift. Repeated CT scan showed a progression of hemorrhage; therefore, the patient underwent right decompressive craniotomy. Despite the definitive management, the patient developed multiple organ failure. A discussion with the family was arranged where they decided to move patient to the inpatient hospice for comfort measures where she eventually died on the 26th day of admission.

**Discussion**

Enterococcus is a major cause of hospital-acquired infections that potentially affect the urinary tract system, soft tissues, heart, and prosthesis. It is known for being resistant to commonly used antibiotics, requiring prolonged antibiotic therapy, and causing significant morbidity and mortality. *Enterococcus* is further classified into *Enterococcus faecalis*, *Enterococcus faecium*, and other rare subtypes. *Enterococcus faecalis* is responsible for 97% of all infective endocarditis caused by Enterococci. Rare subtypes such as *Enterococcus gallinarum*, *Enterococcus avium*, *Enterococcus casseliflavus*, *Enterococcus raffinosus*, *E. durans*, and *Enterococcus hirae* are seldom associated with human infections due to their low infectivity.

*Enterococcus* is the third leading cause of infective endocarditis, following *Streptococcus* and *Staphylococcus*. It is responsible for 5%–20% of all cases of endocarditis. It causes endocarditis in both native and prosthetic valves. Patients with enterococcal endocarditis are relatively older and have significant comorbidities.

*E. durans* is a nonfaecalis and nonfaecium *Enterococcus*. It is a part of gut flora with low virulence. It has a subacute

---

**Figure 1:** Shows the culture and sensitivity on initial presentation of the patient.

![Figure 1](image1.png)

**Figure 2:** (a) Transesophageal echocardiogram done on initial admission shows vegetation on the medial aspect of the annulus of mechanical mitral valve. (b) Transesophageal echocardiogram done on final admission which is negative for any vegetation.
progression of symptoms and rarely associated with peripheral signs such as Osler’s nodes, Roth spots, and petechial lesions. *E. durans* endocarditis is an exceptionally rare entity that has been reported only seven times in the literature. Previous literature has emphasized on reporting *E. durans* as a rare cause of infective endocarditis,[7-10] infective endocarditis on bioprosthetic valve,[11,12] and gentamicin-resistant infective endocarditis.[13] However, there is no evidence in the literature reporting a late prosthetic valve *E. durans* infective endocarditis on a mechanical mitral valve that failed to be eradicated with medical management. In our case, the patient presented with subacute clinical symptoms for 3 months. Endocarditis was diagnosed on the basis of four sets of positive blood cultures, whereas further evidence was provided by the presence of vegetation on transesophageal echocardiography.

The recommended treatment for prosthetic valve enterococcal endocarditis is a combination therapy of beta-lactam and gentamicin for 6 weeks, whereas vancomycin is indicated in cases of ampicillin intolerance. Newer agents such as daptomycin, linezolid, quinupristin-dalfopristin, and other glycopeptides are alternative treatment options.[4,14,15] The ultimate management is through the replacement of the valve when there is the presence of persistent emboli, failure of medical therapy, relapse of infection, cardiac insufficiency, and heart block.[4,10]

In our case, combination therapy of ampicillin and ciprofloxacin was used. Although guidelines suggest combination ampicillin and gentamicin therapy, gentamicin was avoided due to renal compromise.[4] The patient completed the recommended 6 weeks of intravenous antibiotics therapy and the follow-up blood cultures did not show any bacterial growth. Three months after the completion of antibiotic therapy, the patient developed stroke and 4 sets of blood culture were drawn that demonstrated the presence of *E. durans*, whereas the transesophageal echocardiography did not show any vegetation.

The case of persistent and identical *E. durans* bacteremia with the disappearance of vegetation on the repeated TEE suggests that antibiotic therapy only reduced the size of vegetation on the mechanical mitral valve but did not completely eradicate the bacteria. Therefore, it strongly indicates that this was a case of *E. durans* infective endocarditis on a prosthetic valve that failed to be eradicated with medical management alone.

**Conclusion**

A case of late prosthetic mechanical mitral valve endocarditis that failed to be eradicated with medical management is reported in this study for the very first time. *E. durans* endocarditis on a mechanical valve is a complex entity that requires combination therapy for a longer duration. The outcomes of medical therapy are poor, and there is a higher chance of relapse after antibiotics are stopped. The ultimate recommendation for prosthetic valve endocarditis is to undergo valve replacement to avoid any relapse.

**Research quality and ethics statement**

The authors of this manuscript declare that this scientific work complies with reporting quality, formatting, and reproducibility guidelines set forth by the EQUATOR Network. We also certify that we have not plagiarized the contents in this submission and have done a Plagiarism Check.

**Acknowledgments**

We would like to thank Dr. P. Rocco Lasala (Associate Professor at the Department of Microbiology, West Virginia University of Medicine) for providing assistance in the case study.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Carbonnelle E, Grohs P, Jacquier H, Day N, Tenza S, Dewailly A,
et al. Robustness of two MALDI-TOF mass spectrometry systems for bacterial identification. J Microbiol Methods 2012;89:133-6.

2. García-Solache M, Rice LB. The *Enterococcus*: A model of adaptability to its environment. Clin Microbiol Rev 2019;32. pii: e00058-18.

3. Ruoff KL, de la Maza L, Murtagh MJ, Spargo JD, Ferraro MJ. Species identities of enterococci isolated from clinical specimens. J Clin Microbiol 1990;28:435-7.

4. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr., Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015;132:1435-86.

5. Tan CK, Lai CC, Wang JY, Lin SH, Liao CH, Huang YT, et al. Bacteremia caused by non-faecalis and non-faecium *Enterococcus* species at a medical center in Taiwan, 2000 to 2008. J Infect 2010;61:34-43.

6. McDonald JR, Olaison L, Anderson DJ, Hoen B, Miro JM, Eykyn S, et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. Am J Med 2005;118:759-66.

7. Stepanović S, Jovanović M, Lavadinović L, Stosović B, Pelemis M. *Enterococcus durans* endocarditis in a patient with transposition of the great vessels. J Med Microbiol 2004;53:259-61.

8. Vijayakrishnan R, Rapose A. Fatal *Enterococcus durans* aortic valve endocarditis: A case report and review of the literature. BMJ Case Rep 2012; bcr0220125855.

9. Kenzaka T, Takamura N, Kumahe A, Takeda K. A case of subacute infective endocarditis and blood access infection caused by *Enterococcus durans*. BMC Infect Dis 2013;13:594.

10. Zala A, Collins N. *Enterococcus durans* prosthetic valve endocarditis: A previously unreported clinical entity. Heart Lung Circ 2016;25:e133-6.

11. Fallavollita L, Di Gioacchino L, Balestrini F. Bioprosthetic aortic valve endocarditis in association with *Enterococcus durans*. Tex Heart Inst J 2016;43:165-7.

12. Sunbul M, Cerik HO, Cerik B, Gulel O, Leblebicigolu H. *Enterococcus durans* endocarditis. Am J Ther 2018;25:e663-5.

13. Tripodi MF, Locatelli A, Adinolfi LE, Andreana A, Utili R. Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin-resistant enterococci. Eur J Clin Microbiol Infect Dis 1998;17:734-6.

14. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009;30:2369-413.

15. Hoen B. Epidemiology and antibiotic treatment of infective endocarditis: An update. Heart 2006;92:1694-700.